Hepatitis Vaccine Market Infrastructure Growth and Development in US by 2026

Hepatitis Vaccine Market Infrastructure Growth
and Development in US by 2026
Hepatitis Vaccine Market, by Indication (Hepatitis A and Hepatitis B), By
Vaccine Type (Recombinant Vaccine and Inactivated Vaccine) by Distribution
Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) and
by Geography - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Hepatitis is an infectious disease caused due to hepatitis virus type A, B, and C, which leads to liver
associated disease such as Hepatitis A, hepatitis B, hepatitis C, liver cirrhosis, hepatocellular
carcinoma, and liver failure. It may lead to death of infected person. The infection is spread due to
transmission of hepatitis A and hepatitis B virus due contact with body fluids (blood etc.) of infected
person. Hepatitis vaccine are available for prevention of both hepatitis A and hepatitis B which prevents
its occurrence by boosting immunity of the person thereby avoiding complications such as liver failure
and cancer. Infection is most prevalent in children. Globally hepatitis B is more prevalent than hepatitis
A.
Market Dynamics
Hepatitis is one of the most prevalent infectious disease across the globe, it attracted attention from
health bodies such as World Health Organization (WHO) due to its severity. Increasing incidence of
hepatitis worldwide is estimated to drive growth of the Hepatitis Vaccine Market. According to World
Hepatitis Report published in 2017 by WHO, an estimated 325 million people worldwide are living
with chronic hepatitis B virus infection (HBV) or hepatitis C virus (HCV) infection. Moreover, an
estimated 1.34 million deaths in 2015, were caused due to viral hepatitis.
Around 1.75 million people were infected with hepatitis B virus infection (HCV) in 2015. Increasing
global population (live births) is another factor driving growth of the hepatitis vaccine market. As per
statistics given by the World Population Report published in 2017, world population would surpass
mark of 9 billion by 2025 thereby adding more live birth each year. According to guideline published
by WHO, vaccine for hepatitis B has to administer within first 24 hour of the birth in order to prevent
the hepatitis B infection to infant. Furthermore, increased awareness amongst masses about benefits of
hepatitis vaccination would further aid in market growth for the hepatitis vaccine market.
There is attractive opportunity to introduce hepatitis C vaccine as it is one of most prevalent type of
hepatitis after hepatitis B and has no vaccine available for it. Also, currently available vaccine for
hepatitis B are ineffective in many adults along with those suffering from diabetes. In these cases
person do not develop adequate immunity even after two or three shots of vaccine. Therefore, new
improved vaccine could prove beneficial and propel growth of the market.
Competitive Analysis
Key players present in the hepatitis vaccines market are Merck and Company, GlaxoSmithKline,
Sanofi Pasture, CSL Behring GmbH, Novartis AG and Pfizer Inc. Few leading brands in hepatitis
vaccine market are Engerix-B, Havrix (Glaxosmithkline), Recombivax, Vaqta (Merck and Company),
Euvax – Avaxim (Sanofi Pasteur), and Shanvac B (Shantha Biotech)
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1537
Amongst indication, hepatitis B vaccine holds larger market share due to higher prevalence of hepatitis
B infection and presence of different companies in the production and marketing of these vaccine.
Recombinant vaccine is largest shareholder in vaccine type segment as it is most commonly used in the
hepatitis B vaccine. Amongst distribution channel retail pharmacy holds major share.
Market Taxonomy
On the basis of Indication
•Hepatitis A
•Hepatitis B
On the basis of Vaccine Type
•Recombinant Vaccine
•Inactivated Vaccine
On the basis of Distribution Channel
•Hospitals
•Retail Pharmacy
•Online Pharmacy
Regional Dynamics
On the basis of regions, hepatitis vaccine market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the hepatitis
vaccine market, owing to high healthcare spending and availability of robust healthcare infrastructure
in the region. According to Centre for Disease Control (CDC) data in 2016, the U.S. had 0.6 cases per
1, 00,000 population.
Even though this rate of incidence is low as compared to regions such as Asia Pacific and Africa, still
due to highest healthcare spending by U.S. population hepatitis vaccine North America is lucrative
market for hepatitis vaccine market. Asia Pacific has greatest burden of hepatitis (154 million people
with hepatitis B) currently as mentioned in World Hepatitis Report, 2017 and it is attractive market for
hepatitis market due to the larger population getting infected from the hepatitis. According to the WHO,
it is estimated that 2% to 5% of general population is affected chronically in Asia Pacific. Prevalence of
hepatitis B is the highest in Middle East & Africa where adult population is chronically infected.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Hepatitis is one of the most prevalent infectious disease across the globe, it attracted attention from health bodies such as World Health Organization (WHO) due to its severity. Increasing incidence of hepatitis worldwide is estimated to drive growth of the Hepatitis Vaccine Market.

Download Report